Skip to main
Medicinal TB-500

A flat, fast-reading board on the TB-500 research peptide — every thymosin beta-4 study sorted into a status row, with the human-data gaps and the regulatory facts surfaced first.

Research board / sources

TB-500 references: every claim on this board, traced to its source.

The peer-reviewed studies and the FDA regulatory pages behind each status card, with DOIs and PubMed identifiers. Where a finding used full-length thymosin beta-4, the citation makes that plain.

Back to the researchRead the legal status

About this reference list

Every quantitative claim on this site maps to a numbered entry below. The literature entries are peer-reviewed studies and reviews; the regulatory entries are primary FDA pages, cited for the 503A record, the July 2026 advisory-committee meeting, and the compounding framework. The recurring annotation across the list — full-length thymosin beta-4 versus the Ac-LKKTETQ fragment — is the distinction the whole board is built to preserve [1][5]. Full citations, with DOIs and PubMed or FDA URLs, are listed in the references index.

  1. Irobi E, Aguda AH, Larsson M, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. (Establishes the Ac-LKKTETQ / thymosin beta-4 actin-binding identity used throughout.) ↗
  2. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. (Full-length thymosin beta-4, rat wound model.) ↗
  3. Irobi E, Aguda AH, Larsson M, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. (2 Å crystal structure; 1:1 G-actin sequestration by dual-end capping.) ↗
  4. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. (Mouse; PINCH–ILK–Akt; full-length thymosin beta-4.) ↗
  5. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Cited for the absence of completed controlled human trials of the TB-500 fragment and the scarce-human-safety-data status.) ↗
  6. Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. (Human Phase 1; full-length thymosin beta-4; well tolerated to 1260 mg IV.) ↗
  7. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. (Review; consolidated mechanism of full-length thymosin beta-4.) ↗
  8. Sosne G, Rimmer D, Kleinman HK, et al. Activation of pro-resolving pathways mediate the therapeutic effects of thymosin beta-4. Front Immunol. 2024;15:1458684. ↗
  9. Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta4 increases hair growth by activation of hair follicle stem cells. FASEB J. 2004;18(2):385-387. (Rat and mouse; nanomolar thymosin beta-4; bulge stem-cell activation, MMP-2.) ↗
  10. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Lists TB-500 and BPC-157 as unapproved; basis for the WADA, racehorse-detection, and tumor-signal framing.) ↗
  11. Morris DC, Cui Y, Cheung WL, et al. A dose-response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 2014;345(1-2):61-67. (Rat embolic MCAo; 2, 12, 18 mg/kg IP; non-monotonic; optimal modeled ~3.75 mg/kg. Also cited for animal mg/kg dose ranges and the mdx null-strength result context.) ↗
  12. Morris DC, Chopp M, Zhang L, et al. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. ↗
  13. Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 induces hair growth via stem cell migration and differentiation. Ann N Y Acad Sci. 2007;1112:95-103. ↗
  14. Gao X, Liang H, Hou F, et al. Thymosin Beta-4 Induces Mouse Hair Growth. PLoS One. 2015;10(6):e0130040. ↗
  15. Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004;125(2):113-115. ↗
  16. Xiao X, Li S, Jia H, et al. Multiple potential roles of thymosin β4 in the growth and development of hair follicles. J Cell Mol Med. 2021;25(2):570-580. ↗
  17. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Records that TB-500 entered 503A Category 2 with the September 29, 2023 nominated-substances update; on the FDA page dated April 22, 2026, the nomination appears as withdrawn and TB-500 is no longer in Category 2, while the same safety rationale remains.) ↗
  18. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (advisory committee calendar). (Lists "TB-500 (free base)" / "TB-500 acetate" — alongside BPC-157, KPV, and MOTs-C — as substances being considered for inclusion on the 503A Bulks List; an agenda listing, not a decision.) ↗
  19. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Basis for the 503A/503B compounding framework, the bulk-substance eligibility rules, the nomination/PCAC process, and the licensed-prescriber → valid-prescription → 503A/503B access pathway with telehealth as a front-end channel.) ↗
  20. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  21. Zhang Y, et al. Thymosin beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation. Cancer Biol Ther. 2008. ↗
  22. Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  23. Spurney CF, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010. ↗
  24. Delcourt V, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023. ↗